Actavis Launches U.S. Generic Specialty Injectable Portfolio
Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The Company will be... Read More
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
generic speciality injectables
Our Popular Courses
Recent Articles
- Aurobindo Pharma hives off its biosimilars business to subsidiary CuraTeQ Biologics
- Lupin, Mylan receive EUmarketing authorization for Nepexto
- AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
- Roche’s Elecsys IL-6 test received USFDA EUA
- Gilead’s Voluntary Licensing Agreements for Remdesivir with 5 generic companies
- Market Exclusivity Case Study: XIFAXAN (rifaximin)
- FDA Grants Accelerated Approval to Capmatinib for NSCLC
- Aleor Dermaceuticals receives EIR from US FDA for Karakhadi formulation facility
- Lupin introduces ‘Jan Kovid’ helpline for Mumbai citizens
- Bausch + Lomb – Stada Arzneimittel – Xbrane Biopharma – licensing deal for Lucentis biosimilar
- Valneva And Pfizer to Co-Develop and Commercialize Lyme Disease Vaccine, Vla15
- Ipsen agreement with IRICoR & Université de Montréal to acquire exclusive license for discovery-stage oncology programme
- Global Licensing Agreement Case study: ProThera Biologics and Takeda to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)
- Glenmark Foundation rolls out tele-health solution to expand access to quality patient care
- Florio GmbH introducing new digital platform aiming to improve the lives of people with haemophilia
- Gilead Sciences, Second Genome ink collaboration strategic deal in biomarker and inflammatory bowel disease drug discovery
- Who determines when a prescription medicine should be switched to OTC status?
- What is the difference between purity and potency?
- Case Study: US FDA approves erythroid maturation agent, Reblozyl
- Case Study: Compassionate use of remdesivir of Gilead for COVID-19